chartexchange

ALNY
Alnylam Pharmaceuticals, Inc.
stockNASDAQ

At CloseNov 18, 2026 3:59:55 PM EST
149.48USD-4.486%(-7.02)2,518,169
Pre-marketNov 18, 2026 9:15:30 AM EST
156.90USD+0.256%(+0.40)
After-hoursNov 18, 2026 4:46:30 PM EST
149.58USD+0.067%(+0.10)
Loading…
Loading…
Healthcare
Biotechnology
CEO
John Maraganore
HQ
Cambridge, MA, USA
Previous Close
$156.50
Beta
0.61
52-Week High
$479.79 2025-12-03
52-Week Low
$149.18 2026-11-10
SMA 50
$215.05
SMA 200
$273.68
Avg. Vol 10D
3.02M
Avg. Vol 30D
2.65M
Avg. Vol 90D
2.06M
Relative Vol
0.95
133.94M
133.51M
0.4100%
1,700,000
918
ALNY Profile

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

ALNY Performance
PeriodPriceDateChangeBeta
1W159.852026-11-11-6.54%3.235
1M233.292026-10-19-35.96%1.067
3M228.612026-08-18-34.65%1.281
6M286.272026-05-18-47.81%0.400
1Y462.302025-11-18-67.69%0.606
2Y232.272024-11-18-35.68%—
5Y178.982021-11-18-16.53%0.381
ALNY Stock Summary

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stock price today is $149.39, and today's volume is 2,518,169. ALNY is down 4.543% today. The 30 day average volume is 2.65M. ALNY market cap is $20.01B with 133.94M shares outstanding.